NEW YORK (GenomeWeb News) – OpGen has appointed Vadim Sapiro to the post of chief information officer, Nick Stiso to vice president of manufacturing operations, and Judy Macemon to vice president of marketing. The company has also promoted Richard Moore to chief scientific officer.
Sapiro will be responsible for developing OpGen's bioinformatics applications, software, databases, and information technology operations. He joins the company from SAIC-Frederick, where he was senior vice president overseeing the information systems program for the National Cancer Institute. Previously, he was vice president for information technology at the J. Craig Venter Institute.
Stiso will be responsible for all manufacturing operations of OpGen's Argus Whole Genome Mapping Systems consumables and reagents kits. Previously, he held executive-level positions in development and manufacturing operations at Biosite Diagnostics, Accumetrics, Syva, GeneOhm Sciences (now part of Becton Dickinson), and Miles Laboratories.
In her role as vice president of marketing, Macemon will be responsible for the company's product portfolio management commercial strategies and tactics. Before joining OpGen, she was vice president of marketing at Helixis (now part of Illumina), and held senior marketing roles at Life Technologies, Stratagene (now part of Agilent), MicroProbe, and Becton Dickinson.
Moore was promoted to chief scientific officer at OpGen from vice president of diagnostic systems, a position he held since he joined the company in October 2008. In his new role, he will lead the R&D organization and will head up scientific collaborations with the genetics research, public health, and clinical research communities.
Response Genetics has appointed Thomas Bologna as CEO and chairman of the board. Kirk Calhoun, the former chairman, was elected to the newly created position of lead director of the board. Denise McNairn, who has served as interim CEO since July, will continue to serve as vice president, general counsel, and secretary.
Bologna joins the firm from Orchid Cellmark (now part of Laboratory Corporation of America), where he was president and CEO. Prior to that he was president, CEO, and a member of the board of Quorex Pharmaceuticals, which was sold to Pfizer; and chairman, president, and CEO of Ostex International, which was sold to Alere.
MP Biomedicals has named Todd Nelson president and CEO, replacing Milan Panic, founder and CEO, who will remain as chairman of the company. Nelson was most recently CEO of eBioscience, which is in the process of being acquired by Affymetrix.
Prior to eBioscience, Nelson was vice president of global corporate development and strategy at Life Technologies. Before that, he was managing director and head of global life sciences corporate strategy and research at RBC Capital Markets and first vice president of global corporate strategy and economics at Merrill Lynch.
The Medical College of Wisconsin has appointed Amy Lemke as associate professor in the Institute for Health and Society's Center for Bioethics and Medical Humanities. Lemke will lead the center's new Program in Genomics and Ethics, which is conducting research on ethical issues raised by the use of genomic technologies in the clinical setting.
The German Research Foundation has named Matthias Mann and Nikolaus Rajewsky as two of the 11 winners of the 2012 Leibniz Prize. One of the Germany's most prestigious scientific awards, the Leibniz Prize comes with up to €2.5 million ($3.3 million) in cash per award. The awards ceremony will be held on Feb. 27, 2012, in Berlin.
Mann, a director at the Max Planck Institute of Biochemistry, won the award for his development of a number of widely used proteomics techniques and platforms and bioinformatics software.
Rajewsky, a professor at Berlin's Max Delbrück Center for Molecular Medicine, won the accolade for his research that combines mathematics and systems biology. His work has focused on microRNAs and their roles in cancer and other diseases and in controlling cellular processes. He developed a computer program that has made it possible to identify the target genes of microRNAs.
Pressure BioSciences has promoted Joseph Damasio to be VP of finance and administration and to be the company's principle financial officer, according to a company filing with the US Securities and Exchange Commission. Damasio formerly served as accounting manager for the company, and before arriving at Pressure BioSciences he was a senior financial analyst at BearingPoint, an auditor at PricewaterhouseCoopers, and he worked at NEN Life Science Products, a subsidiary of PerkinElmer. As part of the agreement, Damasio was granted incentive stock options to purchase 5,000 shares of the company's common stock at an exercise price of $0.65.
Accelr8's shareholders have re-elected three members of the board of directors, including Thomas Geimer, Charles Gerretson, and John Kucera. Geimer has been chairman since 1987 and also currently serves as CEO and CFO. Gerretson has been a director since 2003, and Kucera has been a director since 2009.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.